MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
7.21
-0.39 (-5.08%)
At close: May 20, 2025, 4:00 PM
7.22
+0.01 (0.08%)
After-hours: May 20, 2025, 4:30 PM EDT
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
28.61M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INKT News
- 5 days ago - MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewsWire
- 15 days ago - MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewsWire
- 2 months ago - MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewsWire
- 2 months ago - MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewsWire
- 3 months ago - MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting - GlobeNewsWire
- 3 months ago - MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting - GlobeNewsWire